Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action inhibitors |
Mechanism CA 242 inhibitors(CA 242 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC26H24FN3O6 |
InChIKeyPLXLYXLUCNZSAA-QLXKLKPCSA-N |
CAS Registry1599440-33-1 |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Colorectal Cancer | Preclinical | France | 20 Apr 2026 | |
| Pancreatic Cancer | Preclinical | France | 20 Apr 2026 |






